Metagenomi Therapeutics
Metagenomi Therapeutics' revenue fell 51.8% to $25 million in fiscal 2025. Its operating margin was −380.9%, down from −170.0% a year earlier. Free cash flow was −$89 million. The diluted share count rose 12.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Metagenomi Therapeutics lost money in fiscal 2025: a net loss of $88 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 271 | 248 | 161 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | — | — | — |
| Current ratio | 4.0x | 6.9x | 7.2x |
| Quick ratio | 4.0x | 6.9x | 7.2x |
Cash flow
Projections
Project Metagenomi Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $23,401 of Metagenomi Therapeutics shares on the open market, and 4 insiders sold $33,075.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Laurence ReidDirector | Bought | 20,000 | $1.17 | $23,401 | Form 4 |
| Sep 8, 2026 | Jian IrishSee Remarks, Director | Sold | 2,140 | $1.16 | $2,482 | Form 4 |
| Sep 8, 2026 | Pamela WapnickChief Financial Officer | Sold | 1,911 | $1.16 | $2,217 | Form 4 |
| Sep 8, 2026 | Matthew WeinSee Remarks | Sold | 358 | $1.16 | $415 | Form 4 |
| Jun 5, 2026 | Jian IrishSee Remarks, Director | Sold | 3,737 | $1.30 | $4,858 | Form 4 |
| Jun 5, 2026 | Pamela WapnickChief Financial Officer | Sold | 2,884 | $1.30 | $3,749 | Form 4 |
| Jun 5, 2026 | Matthew WeinSee Remarks | Sold | 558 | $1.30 | $725 | Form 4 |
| Mar 5, 2026 | Jian IrishChief Executive Officer, Director | Sold | 1,607 | $1.60 | $2,571 | Form 4 |
| Mar 5, 2026 | Pamela WapnickChief Financial Officer | Sold | 1,581 | $1.60 | $2,530 | Form 4 |
| Mar 5, 2026 | Matthew WeinSee Remarks | Sold | 482 | $1.60 | $771 | Form 4 |
| Dec 5, 2025 | Brian C. ThomasDirector | Sold | 3,830 | $1.77 | $6,779 | Form 4 |
| Dec 5, 2025 | Jian IrishChief Executive Officer, Director | Sold | 1,602 | $1.77 | $2,836 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | −197.7% | −406.7% |
| Altman Z'' | 3.13 | −0.61 |
| Accruals ratio | 9.0% | 0.4% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Fail |
| Cash from operations exceeds net income | Fail | Fail |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Pass |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | Fail |
| F-score | — | — |
Compare
Put Metagenomi Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Metagenomi Therapeutics | FY25 | −51.8% | −380.9% | −354.9% | — | — | — | |
| Entrada Therapeutics | FY25 | −87.9% | −621.1% | −509.6% | — | — | — | Compare |
| Alector | FY25 | −79.1% | −741.3% | −874.7% | — | — | 1 | Compare |
| LENZ Therapeutics | FY25 | — | −477.5% | −366.7% | — | — | — | Compare |
| Precision Biosciences | FY25 | −50.1% | −152.2% | −192.4% | — | — | — | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 45 | 52 | 25 |
| Revenue growth | — | 16.8% | −51.8% |
| Gross profit | — | — | — |
| Research and development | 94 | 109 | 94 |
| Operating income | −78 | −89 | −96 |
| Net income | −68 | −78 | −88 |
| Diluted EPS (US$) | −20.05 | −2.36 | −2.36 |
| Diluted shares (millions) | 3 | 33 | 37 |
| Cash flow | |||
| Cash from operations | −91 | −109 | −89 |
| Capital expenditure | 10 | 3 | 1 |
| Free cash flow | −101 | −112 | −89 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 7 | 16 | 12 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 271 | 248 | 161 |
| Debt incl. finance leases | — | — | — |
| Total assets | 365 | 325 | 221 |
| Total liabilities | 150 | 90 | 62 |
| Shareholders' equity | −136 | 235 | 159 |
| Margins and ratios | |||
| Gross margin | — | — | — |
| Operating margin | −175.4% | −170.0% | −380.9% |
| Net margin | −152.5% | −149.3% | −348.5% |
| Free cash flow margin | −226.2% | −214.5% | −354.9% |
| Rule of 40 (growth + FCF margin) | — | −197.7% | −406.7% |
| Return on capital | — | — | — |
| Return on equity | — | −157.3% | −44.7% |
| Return on assets | — | −22.6% | −32.2% |
| Net debt to EBITDA | — | — | — |